Gilead and Novo plot next steps after trial data from NASH c...

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study.

Genfit abandons late-stage trial of NASH drug elafibranor

France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve patient outcomes in a phase 3 study, which has now b

Another NASH setback as CymaBay drops seladelpar

Novartis takes $80M punt on early-stage NASH drug from Plian...

Alnylam hopes for 2018 filing for RNAi liver disease drug

Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018 after unveiling encouraging early-stage data for givosiran in a rare liver disease.<

Novo Nordisk board member quits over NASH conflict of intere...

Mary Szela has quit to avoid a conflict of interest.